A renewed perspective on TCA intermediate cis-aconitate: mechanisms and therapeutic options against influenza virus
Authors:
Open Access
- 16 February 2026
- journal article
- editorial
- Published by Springer Nature in EMBO Molecular Medicine
- Vol. 18 (3) , 855-857
Abstract
Effective therapeutic strategies for influenza, ranging from seasonal flu outbreaks to sporadic pandemics, should ideally combine antiviral efficacy to accelerate viral clearance with targeted immunomodulation to mitigate excessive inflammation. In this issue of EMBO Molecular Medicine, Cezard et al introduce the inhibitory potential of the tricarboxylic acid (TCA) cycle intermediate cis-aconitate against influenza virus. Cis-aconitate is promising for further translational evaluation, as it meets the dual targeting criteria of antiviral and anti-inflammatory activity at both early as well as late stages of infection. Remarkably, these effects occur independently of its conversion into itaconate, a well-characterized immunomodulatory TCA derivative. This novel aspect of cis-aconitate further supports continued consideration of TCA cycle intermediates beyond their canonical metabolic roles. C. Claus and I. Kovacevic discuss the identification of cis-aconitate, a mitochondria-derived metabolite, with dual antiviral and anti-inflammatory activity against influenza, as reported by M. Si-Tahar and colleagues, in this issue of EMBO Mol Med.Keywords
This publication has 8 references indexed in Scilit:
- Cis-aconitate therapy protects against influenza mortality by dual targeting of viral polymerase and ERK/AKT/NF-κB signalingEMBO Molecular Medicine, 2026
- Reprogramming immunity with itaconate: metabolic mechanisms and therapeutic perspectivesInflammation Research, 2025
- Metabolites as regulators of autoimmune diseasesFrontiers in Immunology, 2025
- Influenza H5Nx viruses are susceptible to MEK1/2 inhibition by zapnometinibEmerging Microbes & Infections, 2025
- Antiviral strategies against influenza virus: an update on approved and innovative therapeutic approachesCellular and Molecular Life Sciences, 2025
- Host succinate inhibits influenza virus infection through succinylation and nuclear retention of the viral nucleoproteinThe EMBO Journal, 2022
- The Role of Tricarboxylic Acid Cycle Metabolites in Viral InfectionsFrontiers in Cellular and Infection Microbiology, 2021
- ACOD1 in immunometabolism and diseaseCellular & Molecular Immunology, 2020